Thymoma (WHO types A, AB, B1, B2 and B3)

What changed: Thymoma (WHO types A, AB, B1, B2 and B3)

Every dated change on the records linked to Thymoma (WHO types A, AB, B1, B2 and B3), newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.

Milestone5This record1

FollowWatch this cancer and Saved shows what changed since you last looked.Follow by feed

September 2026 · 1

2026-09-18This recordThymoma (WHO types A, AB, B1, B2 and B3)
Facts on this page last checked
When this page itself was last checked or edited.

2018 · 1

2018MilestoneEverolimus
Everolimus phase 2 shows disease control in pretreated thymic epithelial tumours; severe immune toxicity of PD-1 antibodies in thymoma reported
A milestone in how this cancer is treated.

2017 · 1

2017MilestoneDisease-specific staging and risk systems (FIGO, Ann Arbor, IPI, R-ISS, ELN, IMDC)
TNM staging for thymic tumours adopted in the eighth edition of the AJCC and UICC manuals
A milestone in how this cancer is treated.

2014 · 1

2014MilestoneThymoma (WHO types A, AB, B1, B2 and B3)
GTF2I L424H mutation found in most type A and AB thymomas
A milestone in how this cancer is treated.

1999 · 1

1999MilestoneThymoma (WHO types A, AB, B1, B2 and B3)
WHO histological classification of thymic epithelial tumours (types A to C)
A milestone in how this cancer is treated.

1981 · 1

1981MilestoneDisease-specific staging and risk systems (FIGO, Ann Arbor, IPI, R-ISS, ELN, IMDC)
Masaoka staging system published, later refined by Koga
A milestone in how this cancer is treated.